Clinical trial
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic…
NCT00086840 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00086840 |
|---|---|
| Title | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Official title | A Phase II Study of CCI-779 in Patients With Relapsed, Refractory or Transformed Chronic Lymphocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia |
| Intervention type | Drug, Other |
| Interventions | temsirolimus, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | May 1, 2004 |
| Primary completion | Aug 1, 2005 |
| First posted | Jul 12, 2004 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: